程序性死亡配体1（PD-L1）表达作为晚期非小细胞肺癌预测生物标志物的作用：一项网状荟萃分析。
The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis.
作者信息
Aguiar Pedro N, Santoro Ilka Lopes, Tadokoro Hakaru, de Lima Lopes Gilberto, Filardi Bruno Andraus, Oliveira Pedro, Mountzios Giannis, de Mello Ramon Andrade
机构信息
Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.
Oncoclínicas do Brasil group, São Paulo, Brazil.
出版信息
Immunotherapy. 2016;8(4):479-88. doi: 10.2217/imt-2015-0002.
BACKGROUND
Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer.
METHODS
We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines.
RESULTS
13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06).
CONCLUSION
Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.
背景
肿瘤程序性死亡配体1（PD-L1）表达已在多项非小细胞肺癌试验中得到研究。
方法
我们根据Cochrane协作网指南评估了PD-L1表达的潜在作用。
结果
纳入了13项研究，共1979例患者。在915例PD-L1阴性患者中，这一比例为13%（风险比2.08；95%置信区间：1.49 - 2.91；p < 0.01）。缓解率随PD-L1表达升高而增加（Pearson相关性，r = 0.43）。PD-L1表达还与更好的24周无进展率相关（风险比0.79；95%置信区间：0.71 - 0.89），并且有1年总生存率提高的趋势（风险比0.96；95%置信区间：0.87 - 1.06）。
结论
考虑到这些数据，目前不能将PD-L1过表达视为指导免疫检查点抑制剂治疗的可靠生物标志物。
Zotero 插件